Drug Profile
GW 290569
Latest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Sleep disorder therapies
- Mechanism of Action Melatonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Sleep disorders
Most Recent Events
- 17 Mar 1999 Discontinued-Preclinical for Sleep disorders in United Kingdom (Unknown route)
- 19 Mar 1998 Preclinical development for Sleep disorders in United Kingdom (Unknown route)